Details for Patent: 9,399,774

Which drugs does patent 9,399,774 protect, and when does it expire?

Patent 9,399,774 protects TEGSEDI and is included in one NDA.

This patent has thirty-three patent family members in twenty-four countries.

Summary for Patent: 9,399,774

Patent landscape, scope, and claims:

Title:	Modulation of transthyretin expression
Abstract:	Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
Inventor(s):	Monia; Brett P. (Encinitas, CA), Freier; Susan M. (San Diego, CA), Siwkowski; Andrew M. (Carlsbad, CA), Guo; Shuling (Carlsbad, CA)
Assignee:	Ionis Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:	14/717,746
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 9,399,774

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018		DISCN	Yes	No	9,399,774					TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS

International Family Members for US Patent 9,399,774

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2563920		300963	Netherlands
European Patent Office	2563920		CA 2019 00001	Denmark
European Patent Office	2563920		122019000001	Germany
European Patent Office	2563920		PA2019001	Lithuania
European Patent Office	2563920		2019C/001	Belgium